Status: Not yet recruiting
Iparomlimab and Tuvonralimab Combined With Chemotherapy and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
This study aims to observe and evaluate the efficacy and safety of Iparomlimab and Tuvonralimab（QL-1706） combined with chemotherapy and bevacizumab ± radiotherapy as neoadjuvant therapy in patients with locally advanced rectal cancer, and to explore the value and implications of radiotherapy omission in this setting.
Participants needed: 56
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Zhejiang UniversityUpdated: Aug 18, 2026
Eligibility criteria
The patient voluntarily consents to participate in this study, demonstrates good... [+12]
Clinical stage cT4b and low rectal cancer (tumor located less than 5 cm from the... [+17]